The Effect of Nicotinamide Riboside on Skeletal Muscle Function in Heart Failure Subjects

What Was Tested

The trial (phase 2) is built around NAD+.

It had 1 arm (groups): one (experimental).

The registry classes the interventions as dietary supplement.

More on the Plan

Putting these together, an emerging hypothesis implicates excessive acetylation of mitochondrial proteins with the subsequent blunting of bioenergetic enzyme function, as a mechanism underpinning incomplete flux through OX PHOS resulting in HF progression.

At the same time HF-associated disruption in skeletal muscle metabolic function activates skeletal muscle cytokine production.

These inflammatory programs, in turn, are proposed to contribute towards impaired functional capacity in HF.

These studies would enable a more comprehensive assessment of the role for NR supplementation on skeletal muscle mitochondrial function in subjects with systolic HF.

Who Took Part

Enrollment: 2 actual participants took part.

It was open to people of any sex aged from 18 years up to 75 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

The full record lists 1 inclusion and 0 exclusion criteria.

How the Study Was Run

It was run as a single-group and open-label study.

Being open-label, the NAD+ study did not mask who received what.

Everyone received the same intervention, so there was no separate comparison group inside the trial.

It started in 2018-09-27 with completion listed for 2019-11-18.

It ran at 2 sites in United States (2).

Its stated primary purpose is basic science.

What Was Measured

Researchers chose this as the main measure: Number of Participants Who Had Enhancement of Mitochondrial Function in Skeletal Muscle (time frame: baseline-12 week-16 week).

It also tracked 4 secondary outcomes, for example VO2 Max and Anaerobic Thresholds.

What This Means in Plain Language

Put simply, this is a phase 2 trial of NAD+ in 2 people.

Its size is small, so on its own it can only give an early look.

It ended early (terminated); results are posted on the registry, and this page does not restate them.

More context: the NAD+ compound page, all human trials.